Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuraxis (NRXS) Asset Writedowns and Impairment (2022 - 2025)

Historic Asset Writedowns and Impairment for Neuraxis (NRXS) over the last 4 years, with Q3 2025 value amounting to $11598.0.

  • Neuraxis' Asset Writedowns and Impairment rose 26760.7% to $11598.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5359.0, marking a year-over-year decrease of 8725.78%. This contributed to the annual value of $7395.0 for FY2024, which is 7074.88% down from last year.
  • According to the latest figures from Q3 2025, Neuraxis' Asset Writedowns and Impairment is $11598.0, which was up 26760.7% from -$15761.0 recorded in Q4 2024.
  • Neuraxis' Asset Writedowns and Impairment's 5-year high stood at $21307.0 during Q2 2022, with a 5-year trough of -$23290.0 in Q4 2022.
  • Over the past 4 years, Neuraxis' median Asset Writedowns and Impairment value was $7040.5 (recorded in 2023), while the average stood at $4625.5.
  • The largest annual percentage gain for Neuraxis' Asset Writedowns and Impairment in the last 5 years was 46002.11% (2024), contrasted with its biggest fall of 18338.71% (2024).
  • Over the past 4 years, Neuraxis' Asset Writedowns and Impairment (Quarter) stood at -$23290.0 in 2022, then surged by 181.16% to $18901.0 in 2023, then tumbled by 183.39% to -$15761.0 in 2024, then surged by 173.59% to $11598.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $11598.0 for Q3 2025, versus -$15761.0 for Q4 2024 and $3155.0 for Q3 2024.